<!DOCTYPE html>
<html class="no-js">

<head>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<title>Cáncer Genitourinario</title>
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<meta name="description" content="Cáncer Genitourinario" />
	<meta name="keywords" content="oncologia, medicina" />
	<meta name="author" content="e-oncologia" />

	<link rel="shortcut icon" type="image/png" href="images/logopeque.png" />

	<link href="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" rel="stylesheet">
	<link href='https://fonts.googleapis.com/css?family=Montserrat:400,700' rel='stylesheet' type='text/css'>

	<link rel="stylesheet" href="css/animate.css">
	<link rel="stylesheet" href="css/icomoon.css">
	<link rel="stylesheet" href="css/bootstrap.css">
	<link rel="stylesheet" href="css/owl.carousel.min.css">
	<link rel="stylesheet" href="css/owl.theme.default.min.css">
	<link rel="stylesheet" href="css/style.css">
	<script src="js/modernizr-2.6.2.min.js"></script>

</head>

<body>

	<div id="ico-page">
		<a href="#" class="js-ico-nav-toggle ico-nav-toggle"><i></i></a>

		<aside id="ico-aside" role="complementary" class="border js-fullheight" style="background-image: url(images/BGoscuro.jpg);">
			<p><br></p>
			<h2 id="ico-logo"><a href="index.html"><img src="images/logo.png" height="80"></a></h2>
			<nav id="ico-main-menu" role="navigation">
				<ul>
					<li><a href="m1u0.html"><span class="bgdestacado2">PRESENTACIÓN</span></a></li>
					<br>
					<li><a href="m1u1.html"><span class="bgdestacado2">MÓDULO 1</span><br>TUMORES UROTERIALES</a></li>
					<br>
					<li><a href="m2u1.html"><span class="bgdestacado2">MÓDULO 2</span><br>CÁNCER RENAL</a></li>
					<br>
					<li><a href="m3u1.html"><span class="bgdestacado2">MÓDULO 3</span><br>TUMORES GERMINALES</a></li>
					<br>
					<li><a href="m5u1.html"><span class="bgdestacado2">BIBLIOGRAFÍA </a></li>
					
				</ul>
			</nav>
		</aside>

		<div id="ico-main">

			<div class="ico-cabeceraVERDE">
				<div class="ico-narrow-content animate-box">
					<h4 class="text-center blanco">Bibliografía</h4>
			<img src="images/ICONObiblio.png" alt="" class="img-responsive centrada">
				</div>
			</div>

			<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<br>
						<h1>Bibliografía</h1>
					</div>
				</div>
			</div>
			<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<h3 id="1">Cáncer urotelial</h3>
						<p class="marcoOSCURO"><span class="verde">Glaser AP, Fantini D, Shilatifard A, Schaeffer EM, Meeks JJ.</span> The evolving genomic landscape of urothelial carcinoma [published online ahead of print, 2017 Feb 7]. Nat Rev Urol. 2017;14(4):215-229. doi:10.1038/nrurol.2017.11.</p>
						<p class="marcoOSCURO"><span class="verde">Moss TJ, Qi Y, Xi L, et al.</span> Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017;72(4):641-649. doi:10.1016/j.eururo.2017.05.048. (20.36.IARC. IARC Monographs on the evaluation of the carcinogenic risks to humans, Vol 61: Schistosomes, liver flukes, and Helicobacter pylori. International Agency for Research on Cancer, Lyon. 1994.37.</p>
						<p class="marcoOSCURO"><span class="verde">Mostafa MH, Sheweita SA, O’Connor PJ.</span> Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. Jan 1999;12(1):97-111 Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-3044).</p>
						<p class="marcoOSCURO"><span class="verde">Miller LS.</span> Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer. 1977; 39(2 Suppl): 973-80.</p>
						<p class="marcoOSCURO"><span class="verde">Huncharek M, Muscat J, Geschwind JF.</span> Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res 1998;18:1931–4.</p>
						<p class="marcoOSCURO"><span class="verde">Slack NH, Bross ID, Prout GR.</span> Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 1977;9:393–405.</p>
						<p class="marcoOSCURO"><span class="verde">Widmark A, Flodgren P, Damber JE, et al.</span> A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 2003;42:567–81.</p>
						<p class="marcoOSCURO"><span class="verde">Smith JA Jr, Crawford ED, Paradelo JC, Blumenstein B, Herschman BR, Grossman HB, Christie DW J Urol.</span> Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. 1997 Mar;157(3):805-7; discussion 807-8.</p>
						<p class="marcoOSCURO"><span class="verde">Granfors T, Tomic R, Ljungberg B. </span>Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. Scand J Urol Nephrol 2009;43:293–9.</p>
						<p class="marcoOSCURO"><span class="verde">Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. </span>Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control. 2013 Jul;20(3):188-99. Review.</p>
						<p class="marcoOSCURO"><span class="verde">Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD.</span> (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2901 – 2907.</p>
						<p class="marcoOSCURO">Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202-206. doi:10.1016/j.eururo.2005.04.006.</p>
						<p class="marcoOSCURO"><span class="verde">Yin M, Joshi M, Meijer RP, et al.</span> Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016;21(6):708-715. doi:10.1634/theoncologist.2015-0440.</p>
						<p class="marcoOSCURO"><span class="verde">James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA.</span> BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477-88. doi: 10.1056/NEJMoa1106106.).</p>
						<p class="marcoOSCURO"><span class="verde">Bos MK, Marmolejo RO, Rasch CR, Pieters BR. </span>Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle- invasive bladder cancer: a systematic review.J Contemp Brachytherapy. 2014 Jun;6(2):191-9.</p>
						<p class="marcoOSCURO"><span class="verde">Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F.</span> Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer. 2004 Dec 1;101(11):2540-8.</p>
						<p class="marcoOSCURO"><span class="verde">Canyilmaz E, Yavuz MN, Serdar L, Uslu GH, Zengin AY, Aynaci O, Haciislamoglu E, Bahat Z, Yoney A.</span> Long-term Outcomes in Treatment of Invasive Bladder Cancer With Concomitant Boost and Accelerated Hyperfractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):562-9.)</p>
						<p class="marcoOSCURO"><span class="verde">Pos FJ, Hart G, Schneider C, Sminia P.</span> Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1168- 73.).</p>
						<p class="marcoOSCURO"><span class="verde">Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, Crundwell M, Adab FA, Sheehan D, Syndikus I, Hendron C, Lewis R, Waters R, James ND.</span> Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys2013, 87:261–269.</p>
						<p class="marcoOSCURO"><span class="verde">Kron T, Wong J, Rolfo A, Pham D, Cramb J, Foroudi F.</span> Adaptiveradiotherapy for bladder cancer reduces integral dose despite dailyvolumetric imaging. Radiother Oncol 2010, 97:485– 487.</p>
						<p class="marcoOSCURO"><span class="verde">Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. </span>Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912–8.</p>
						<p class="marcoOSCURO"><span class="verde">Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, Hoskin PJ, West CM. </span>Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol. 2013 Jul;108(1):40-7.</p>
						<p class="marcoOSCURO"><span class="verde">Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W.</span> Eur Urol. 2014 Jul;66(1):120-37.Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.</p>
						<p class="marcoOSCURO"><span class="verde">Dhar NB, Campbell SC, Zippe CD, Derweesh IH, Reuther AM, Fergany A, et al.</span> Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int. 2006; 98: 1172-5.</p>
						<p class="marcoOSCURO"><span class="verde">Birtle A, Johnson M, Chester J, et al. </span> Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268-1277. doi:10.1016/S0140-6736(20)30415-3.</p>
						<p class="marcoOSCURO"><span class="verde">Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, et al.</span> Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010; 183: 2165-70.</p>
						<p class="marcoOSCURO"><span class="verde">Zaghloul MS. </span>Adjuvant radiation therapy for locally advanced bladder cancer. Touchbriefings, US oncological disease issue 2006;2:86–9).</p>
						<p class="marcoOSCURO"><span class="verde">Jose CC, Price A, Norman A, Jay G, Huddart R, Dearnaley DP, Horwich A.</span> Hypofractionated radiotherapy for patients with carcinoma of the bladder.Clin Oncol (R Coll Radiol). 1999;11(5):330-3.</p>
						<p class="marcoOSCURO"><span class="verde">Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, Fossâ SD, Uscinska BM, Parmar MK.</span> A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: resultsof medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47: 379-88.</p>
						<p class="marcoOSCURO">NCCN Guidelines 2020 Bladder Cancer.</p>
						<p class="marcoOSCURO"><span class="verde">Alfred Witjes J, Lebret T, Compérat EM, et al.</span> Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71(3):462-475. doi:10.1016/j.eururo.2016.06.020.</p>
						<p class="marcoOSCURO"><span class="verde">Rouprêt M, Babjuk M, Burger M, et al. </span> European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update [published online ahead of print, 2020 Jun 24]. Eur Urol. 2020;S0302-2838(20)30427-9.</p>
						<p class="marcoOSCURO"><span class="verde">Galsky MD, Arija JÁA, Bamias A, et al. </span> Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557. doi:10.1016/S0140-6736(20)30230-0.</p>
						<br>

						<h3 id="2">Cáncer renal</h3>
						
						<p class="marcoOSCURO"><span class="verde">Brugarolas J.</span> Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32(18):1968-1976. doi:10.1200/JCO.2012.45.2003.</p>
						<p class="marcoOSCURO">Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016;374(2):135-145. doi:10.1056/NEJMoa1505917</p>
						<p class="marcoOSCURO"><span class="verde">Lee J., Hodgson D., Chow E., Bezjak A., Catton P., Tsuji D., O'Brien M., Danjoux, C., Hayter C., Warde P., et al. </span> A phase II trial of palliative radiotherapy for metastatic renal cellcarcinoma. Cancer 2005, 104, 1894-1900.</p>
						<p class="marcoOSCURO"><span class="verde">Wrónski M., Maor M.H., Davis B.J., Sawaya R., Levin V.A. </span>External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the MD Anderson Cancer Center. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37, 753-759.</p>
						<p class="marcoOSCURO"><span class="verde">Shaw E., Scott C., Souhami L., Dinapoli R., Kline R., Loeffler J., Farnan N.</span> Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of rtog protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47, 291-298.</p>
						<p class="marcoOSCURO"><span class="verde">Fokas E., Henzel M., Hamm K., Surber G., Kleinert G., Engenhart-Cabillic R. </span> Radiotherapy for brain metastases from  renal cell cancer: Should whole-brain radiotherapy be added to stereotactic radiosurgery: Analysis of 88 patients. Strahlenther. Onkol. 2010, 186, 210-217. ¡</p>
						<p class="marcoOSCURO"><span class="verde">Blanco AI, Teh BS, Amato RJ. </span>Role of radiation therapy in the management of renal cell cancer. Cancers (Basel). 2011 Oct 26;3(4):4010-23.</p>
						<p class="marcoOSCURO"><span class="verde">Muacevic A., Kreth F.W., Mack A., Tonn J.C., Wowra B. </span> Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim. Invasive Neurosurg. 2004, 47, 203-208.</p>
						<p class="marcoOSCURO"><span class="verde">Chang E.L., Wefel J.S., Hess K.R., Allen P.K., Lang F.F., Kornguth D.G., Arbuckle R.B., Swint J.M., Shiu A.S., Maor M.H., et al.</span> Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol. 2009, 10, 1037-1044).</p>
						<p class="marcoOSCURO"><span class="verde">Teh B., Bloch C., Galli-Guevara M., Doh L., Richardson S., Chiang S., Yeh P., Gonzalez M., Lunn W., Marco R., et al. </span> The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT).</p>
						<p class="marcoOSCURO">NCCN Guidelines 2020 Kidney Cancer.</p>
						<p class="marcoOSCURO">Biomed. Imaging Interv. J. 2007.</p>
						<p class="marcoOSCURO"><span class="verde">Gerszten P.C., Burton S.A., Ozhasoglu C., Vogel W.J., Welch W.C., Baar J., Friedland D.M.</span> Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J. Neurosurg. 2005, 3, 288- 295.</p>
						<p class="marcoOSCURO"><span class="verde">Barney BM, Markovic SN, Laack NN, Miller RC, Sarkaria JN, Macdonald OK, Bauer HJ, Olivier KR.</span> Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy nt J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):73-80.</p>
						<p class="marcoOSCURO"><span class="verde">Staehler M, Haseke N, Nuhn P, Tüllmann C, Karl A, Siebels M, Stief CG, Wowra B, Muacevic A.</span> Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma.BJU Int. 2011 Sep;108(5):673-8.</p>
						<p class="marcoOSCURO"><span class="verde">Rini BI, Plimack ER, Stus V, et al.</span> Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-1127.</p>
						<p class="marcoOSCURO"><span class="verde">Motzer RJ, Penkov K, Haanen J, et al.</span> Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047.</p>
						<p class="marcoOSCURO"><span class="verde">Motzer RJ, Tannir NM, McDermott DF, et al.</span> Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126.</p>
						

					



						<h3 id="3">Tumores germinales</h3>
						<p class="marcoOSCURO"><span class="verde">Chung P, Mayhew LA, Warde P, Winquist E, Lukka H.</span> Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (RColl Radiol) 2010; 22: 6–16.</p>
						<p class="marcoOSCURO"><span class="verde">Oldenburg J1, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V.</span> ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi125-32.</p>
						<p class="marcoOSCURO"><span class="verde">Van den Belt-Dusebout AW, Nuver J, de Wit R et al.</span> Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467–475.</p>
						<p class="marcoOSCURO"><span class="verde">Huddart RA, Norman A, Shahidi M et al.</span> Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513–1523.</p>
						<p class="marcoOSCURO"><span class="verde">Cummins S, Yau T, Huddart R, Dearnaley D, Horwich A.</span> Surveillancein stage I seminoma patients: a long-term assessment. Eur Urol 2010; 57:673–8.</p>
						<p class="marcoOSCURO"><span class="verde">Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, StormH, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES.</span> Second cancers among 40,576 testicular cancer patients: focus on longterm survivors. J Natl Cancer Inst 2005, 97(18):1354-65.</p>

						

						
					</div>
				</div>
			</div>
			
			

			
		




	
		

			

		



		


		
		

			

			

			

		
					

		

		

		









			<div class="ico-cabecera">
				<div class="ico-narrow-content">
					<div class="pager">
						<br>
					</div>
				</div>
			</div>










		</div>
	</div>

	<!-- jQuery -->
	<script src="js/jquery.min.js"></script>
	<!-- jQuery Easing -->
	<script src="js/jquery.easing.1.3.js"></script>
	<!-- Bootstrap -->
	<script src="js/bootstrap.min.js"></script>
	<!-- Carousel -->
	<script src="js/owl.carousel.min.js"></script>
	<!-- Stellar -->
	<script src="js/jquery.stellar.min.js"></script>
	<!-- Waypoints -->
	<script src="js/jquery.waypoints.min.js"></script>
	<!-- Counters -->
	<script src="js/jquery.countTo.js"></script>
	<!-- MAIN JS -->
	<script src="js/main.js"></script>
	<!-- partial -->
	<script src='https://cdnjs.cloudflare.com/ajax/libs/vue/2.5.13/vue.min.js'></script>
	<script src="js/scriptdiagram.js"></script>

</body>

</html>
